Aura Biosciences (AURA) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aura Biosciences (AURA) has outperformed MeiraGTx (MGTX) over the past year, gaining 26.3% versus a gain of 7.0%. Over five years, MGTX leads with a -55.5% price change compared with -69.6% for AURA. MeiraGTx is the larger company by market cap ($779.9 million vs $715.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | MGTX |
|---|---|---|
| Share price | $6.87 | $7.98 |
| Market cap | $714.99M | $779.89M |
| 1-day change | -1.58% | -1.97% |
| YTD return | +26.06% | +0.38% |
| 1-year return | +26.29% | +6.97% |
| 5-year return | -69.63% | -55.54% |
| P/E ratio (TTM) | — | 9.17 |
| EPS (TTM) | $-1.59 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $81.39M |
| Revenue growth (YoY) | — | +144.57% |
| Net income (latest FY) | $-106.19M | $-114.20M |
| Operating margin | — | -130.20% |
| Net margin | — | -140.31% |
| 52-week high | $9.54 | $15.35 |
| 52-week low | $4.73 | $6.62 |
| Distance from 52-week high | -27.95% | -48.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +141.63% | +247.74% |
| Average volume | 847.22K | 837.25K |
| Shares outstanding | 104.07M | 97.73M |
| Employees | 113 | 386 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AURA has outperformed MGTX by 19.3 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees
AURA vs MGTX FAQ
Which is bigger, Aura Biosciences or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $779.89M compared with $714.99M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or MGTX?
AURA returned +26.29% over the past 12 months, compared with +6.97% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.